Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Will AstraZeneca's headache continue?
Thursday 27 April
Investors are already forewarned of a tough 2017 for pharmaceutical business AstraZeneca (AZN) after guidance in February for a low to mid-single digit sales decline.
We believe investors will want an update on cholesterol treatment Crestor in its trading update on 27 April after a 13% drop in sales following patent expiry.
The market will also be looking for clarity on which new drugs it will bring to market to replenish its portfolio.